reason report
data on-track initi
bottom line see approach critic inflect point
on-demand hereditari angioedema
data expect read posit result could lift stock
reason -- de-risk ahead like similar trial design
increas optim prophylaxi may
also yield posit result ground biolog target
plasma kallikrein pkal inhibit report cash
balanc think compani suffici cash runway
achiev data initi
reiter op pt
data mark near-term inflect point --
remain optimist base favor pharmacokinet pk
pharmacodynam pd properti accompani clean safeti profil
continu view potenti disrupt medicin
acut set berotralstat pursu
prophylaxi set approv anticip pdufa
japan envis berotralstat launch prime market
oral medicin yet approv like leav acut market
untap thu posit outcom may lead
streamlin trial execut prior enter attract
market management current estim total market per yr us
meanwhil given remain lead candid
clinic program see upcom data catalyst
import inflect point stock
studi on-track initi data could
provid posit readthrough light share underli biolog
-- pkal inhibit -- think data provid meaning
insight probabl success caveat
yet provid data -- anticip -- posit
result like bolster investor sentiment pkal inhibit
demonstr robust therapeut benefit oral
administ drug potent inject
product optim remain on-going trial initi
edema dme back burner cash
program remain top prioriti consequ
despit intrigu observ studi link
expir option agreement op like push
develop later view
blend revenu multipl
analysi dcf disc rate
year price history/av daili volume mil
compani inform svb leerink llc research
fy end april mm
pleas refer page import disclosur price chart analyst certif
lead asset address hereditari angioedema pend favor efficaci
safeti profil oral administr key differenti legaci entrant
ascrib po ww gener peak sale
follow-on asset intravitr ivt -administ agent subset diabet
macular edema dme patient ascrib po ww gener royalti
payment peak
futur opportun may includ prophylaxi market and/or indic wherein
inhibit plasma kallikrein may deliv clinic benefit
broadli focus discoveri develop commerci small
molecul proteas inhibitor new treatment diseas signific unmet need
deriv one-year pt base blend dcf analysi revenu
multipl analysi assign valu probability-weight sale po
hereditari angioedema royalti stream po diabet macular
edema dme addit program indic collabor may present upsid
estim matur clinical-stag compani use discount rate termin
clinical-stag compani risk includ clinic regulatori financi
heavy-weight valuat add signific binari risk head data
readout favor pk/pd may translat differenti clinic profil patient
eventu uptak prophylaxi therapi takhzyro haegarda repercuss
size acute/on-demand market
futur program bring forth share risk irrespect progress
success earlier agent
full safeti profil includ long-term exposur plasma kallikrein pkal inhibitor remain
commerci uptak and/or evolut competit landscap
impact legaci entrant and/or gener drug
total incom
chang cash
proce common stock
proce convertible/debt
issuanc warrants/opt
discount rate/cost equiti
